- Home
- CNTY vs ATRA Comparison
CNTY vs ATRA Comparison
Compare CNTY & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTY | ATRA |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8M | 38.9M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CNTY | ATRA |
|---|---|---|
| Price | $1.18 | $7.94 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 2 | 2 |
| Target Price | $3.00 | ★ $5.00 |
| AVG Volume (30 Days) | 56.1K | ★ 69.3K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.31 | ★ 122.52 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $430,529,000.00 | $120,772,000.00 |
| Revenue This Year | $7.17 | N/A |
| Revenue Next Year | $3.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.82 | N/A |
| 52 Week Low | $1.14 | $3.92 |
| 52 Week High | $2.85 | $19.15 |
Technical Indicators
Market Signals| Indicator | CNTY | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 34.90 | 37.41 |
| Support Level | $1.14 | $4.35 |
| Resistance Level | $1.47 | $11.17 |
| Average True Range (ATR) | 0.04 | 0.69 |
| MACD | -0.00 | -0.20 |
| Stochastic Oscillator | 15.79 | 4.09 |
Price Performance
Historical ComparisonAbout CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has five reportable segments based on the geographical locations in which its casinos operate; US East, US Midwest, US West, Canada, and Poland.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).